News
Biogen touted an “unprecedented” drop in tau in a Phase 2 trial, backing the company’s decision to take diranersen to Phase 3 despite a missed primary endpoint and seemingly supporting the anti-tau approach.
FEATURED STORIES
As antibody-drug conjugates advance and move into earlier lines of treatment, drug developers have to build gentler therapies that don’t just extend survival but improve it.
FDA’s rare disease decisions are strongest when the patient community has a voice in advisory committee decisions.
The lineup at the Alzheimer’s Association International Conference will provide critical insight into where the industry is headed with regard to targets being explored to vanquish the elusive neurodegenerative disease.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
THE LATEST
The deal’s termination was announced Thursday, months after bintrafusp alfa failed to hit the mark in a Phase II clinical trial as a potential second-line treatment for metastatic biliary tract cancer.
It was a busy week for clinical trial news. Here’s a look.
First COVID-19, now cancer. BioNTech made history when its COVID-19 mRNA vaccine with partner Pfizer became the first ever approved.
Investment firm Avoro Capital has raised concerns that the $180 per-share price Merck is paying Acceleron Pharma undervalues the rare-disease focused company.
Noninvasive tests for colorectal cancer, prostate cancer and COVID-19 were among the highlights of the American Association for Clinical Chemistry meeting September 26-30.
The Phase III trial on a potential treatment for mild-to-moderate COVID-19 symptoms by Merck and Ridgeback Biotherapeutics showed promise in preventing hospitalizations and death.
As the city rapidly develops as a biopharma hub, wet lab space is rapidly dwindling.
The companies said the collaboration recognizes a “great need for novel treatments in the area of neuropsychiatric medicine development.”
The Pfizer-BioNTech booster shot is now authorized for people over 18 and 65 who are immunocompromised, at high risk due to their work or living situation and front-line healthcare workers.
Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.